BetterLife Pharma (STU:NPAU) FCF Margin % : 0.00% (As of Jan. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BetterLife Pharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BetterLife Pharma's Free Cash Flow for the three months ended in Jan. 2024 was €-0.17 Mil. BetterLife Pharma's Revenue for the three months ended in Jan. 2024 was €0.00 Mil. Therefore, BetterLife Pharma's FCF Margin % for the quarter that ended in Jan. 2024 was 0.00%.

As of today, BetterLife Pharma's current FCF Yield % is -18.36%.

The historical rank and industry rank for BetterLife Pharma's FCF Margin % or its related term are showing as below:

STU:NPAU's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -139.31
* Ranked among companies with meaningful FCF Margin % only.

BetterLife Pharma FCF Margin % Historical Data

The historical data trend for BetterLife Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma FCF Margin % Chart

BetterLife Pharma Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

FCF Margin %

Get a 7-Day Free Trial

BetterLife Pharma Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BetterLife Pharma's FCF Margin %

For the Biotechnology subindustry, BetterLife Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BetterLife Pharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BetterLife Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BetterLife Pharma's FCF Margin % falls into.

BetterLife Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BetterLife Pharma's FCF Margin for the fiscal year that ended in Jan. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Jan. 2024 )	/	Revenue (A: Jan. 2024 )
	=	-1.691	/	0
	=	%

BetterLife Pharma's FCF Margin for the quarter that ended in Jan. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jan. 2024 )	/	Revenue (Q: Jan. 2024 )
	=	-0.174	/	0
	=	%

BetterLife Pharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BetterLife Pharma (STU:NPAU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (STU:NPAU) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BETRF:USA NPAU:Germany BETR:Canada

Address

1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6

Website

https://www.abetterlifepharma.com

BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.

BetterLife Pharma (STU:NPAU) Headlines

No Headlines